Aarti Pharmalabs Limited

rs,

September 23, 2025 To, Listing/ Compliance Department BSE LTD. Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001 SCRIP CODE: 543748 Dear Sir/Madam, To, Listing/ Compliance De

20%

220+ Products 500+ Global Clients 58 6 3 Patents Filed Manufacturing Units USFDA Units 15-20% Global Market Share in Xanthine 50+ Export Countries 2,100+ Employees 3 State-of-the-art R&

0.19x

50+ Export Countries 2,100+ Employees 3 State-of-the-art R&D facilities 50 31 US DMF CEP 0.19x Net Debt/Equity A+ Credit rating Aarti Pharmalabs Limited 2 COMPANY OVERVIEW • Aarti Pharma

INR 130

ited (APL) is part of the Aarti group – a diversified chemical conglomerate with group turnover of INR 130+ bn (FY25) • Globally recognized manufacturer of generic API, Xanthine derivatives and a leading p

19%

OFEPRIS (Mexico) STANDALONE REVENUE (INR Mn) & EBITDA MARGINS (%) 15,112 15,021 17,714 9,410 19% 20% 23% 24% • Strategically located in western India with proximity to ports 9M-FY22 FY23 FY

23%

exico) STANDALONE REVENUE (INR Mn) & EBITDA MARGINS (%) 15,112 15,021 17,714 9,410 19% 20% 23% 24% • Strategically located in western India with proximity to ports 9M-FY22 FY23 FY24 FY25

24%

) STANDALONE REVENUE (INR Mn) & EBITDA MARGINS (%) 15,112 15,021 17,714 9,410 19% 20% 23% 24% • Strategically located in western India with proximity to ports 9M-FY22 FY23 FY24 FY25 HIGHL

48%

ertise in novel chemistries; Largest manufacturer of Xanthine Derivatives in India Domestic, 48% International, 52% Aarti Pharmalabs Limited Note: FY22 numbers are for a period of 9 months as

52%

istries; Largest manufacturer of Xanthine Derivatives in India Domestic, 48% International, 52% Aarti Pharmalabs Limited Note: FY22 numbers are for a period of 9 months as the demerger date was

21 MW

for a period of 9 months as the demerger date was 1st Jul 2021 3 KEY MILESTONES 2024 • Started 21 MW solar power project at Akola, Maharashtra Expansion of semi-commercial production block at Vapi •

52.6%

QUARTERLY REVENUE BREAK-UP Xanthine Derivatives & Allied Products API & Intermediates CDMO/CMO 52.6% 36.1% 11.3% FY24 43.5% 43.6% 12.9% FY25 34.3% 38.8% 26.9% Q4-FY25 CDMO/CMO API & Inter

36.1%

RLY REVENUE BREAK-UP Xanthine Derivatives & Allied Products API & Intermediates CDMO/CMO 52.6% 36.1% 11.3% FY24 43.5% 43.6% 12.9% FY25 34.3% 38.8% 26.9% Q4-FY25 CDMO/CMO API & Intermediate